ICU Medical, Inc. $ICUI Shares Bought by MetLife Investment Management LLC

Key Points

• MetLife Investment Management LLC increased its stake in ICU Medical, Inc. by 850.4%, owning approximately 0.50% of the company valued at $17.09 million following the purchase of 110,095 additional shares.
• ICU Medical reported earnings of $2.10 per share for the last quarter, exceeding analysts' expectations of $1.44, although the company's revenue decreased 8.0% year-over-year.
• Recent insider activity includes CEO Vivek Jain acquiring 21,929 shares at an average cost of $112.84, increasing his ownership stake by 20.26%.

MetLife Investment Management LLC lifted its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 850.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 123,041 shares of the medical instruments supplier's stock after buying an additional 110,095 shares during the period. MetLife Investment Management LLC owned approximately 0.50% of ICU Medical worth $17,085,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the stock. Ameriprise Financial Inc. raised its stake in ICU Medical by 18.5% in the 1st quarter. Ameriprise Financial Inc. now owns 693,711 shares of the medical instruments supplier's stock worth $96,326,000 after acquiring an additional 108,493 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of ICU Medical by 17,559.7% in the first quarter. GAMMA Investing LLC now owns 99,424 shares of the medical instruments supplier's stock valued at $138,060,000 after purchasing an additional 98,861 shares during the period. Point72 Asset Management L.P. raised its stake in shares of ICU Medical by 63.2% in the fourth quarter. Point72 Asset Management L.P. now owns 245,340 shares of the medical instruments supplier's stock worth $38,069,000 after purchasing an additional 95,030 shares during the last quarter. Pacific Capital Partners Ltd acquired a new stake in shares of ICU Medical during the first quarter worth about $12,845,000. Finally, Invesco Ltd. boosted its position in ICU Medical by 80.1% in the first quarter. Invesco Ltd. now owns 203,827 shares of the medical instruments supplier's stock valued at $28,303,000 after buying an additional 90,674 shares during the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

ICU Medical Stock Performance

ICU Medical stock traded up $0.42 during mid-day trading on Thursday, hitting $127.04. The company had a trading volume of 219,661 shares, compared to its average volume of 268,155. The company has a market capitalization of $3.14 billion, a price-to-earnings ratio of -83.58 and a beta of 0.88. ICU Medical, Inc. has a 12-month low of $107.00 and a 12-month high of $196.26. The company's fifty day moving average is $126.90 and its 200-day moving average is $136.37. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The firm had revenue of $543.57 million during the quarter, compared to analysts' expectations of $543.33 million. During the same period in the previous year, the business posted $1.56 EPS. The business's revenue was down 8.0% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Equities research analysts predict that ICU Medical, Inc. will post 4.11 EPS for the current year.

Analyst Upgrades and Downgrades

ICUI has been the topic of several research reports. Piper Sandler initiated coverage on shares of ICU Medical in a report on Friday, August 15th. They issued an "overweight" rating and a $145.00 price target on the stock. Wall Street Zen downgraded shares of ICU Medical from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Finally, Raymond James Financial reduced their target price on shares of ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, ICU Medical presently has a consensus rating of "Buy" and a consensus target price of $179.00.

Insider Transactions at ICU Medical

In other ICU Medical news, Director David C. Greenberg purchased 1,200 shares of ICU Medical stock in a transaction that occurred on Wednesday, August 27th. The stock was bought at an average price of $126.42 per share, with a total value of $151,704.00. Following the acquisition, the director owned 7,960 shares of the company's stock, valued at $1,006,303.20. This trade represents a 17.75% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Vivek Jain acquired 21,929 shares of the company's stock in a transaction on Thursday, August 14th. The stock was acquired at an average cost of $112.84 per share, for a total transaction of $2,474,468.36. Following the completion of the acquisition, the chief executive officer owned 130,149 shares of the company's stock, valued at $14,686,013.16. This trade represents a 20.26% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 1.50% of the company's stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.